Jonathan Neal | Head Pipeline & Portfolio Europe & Canada
Takeda

Jon was appointed in April 2022 as the Head of Portfolio & Pipeline – EUCAN within the Takeda Regional HQ in Zurich.  In this role, Jon leads a team of therapy area aligned Franchise Heads and together they provide strategic direction and support to the Local Operating Companies and to Global commercial and R&D organisation to help ensure the commercial success of both our currently marketed medicines and our pipeline products in Europe and Canada. This involves understanding the policy and access requirements across the region and designing the commercial strategies that will help ensure all patients can access our medicines and we have the right strategies and investments to maximise the benefits to patients, health systems and Takeda. Previously, Jon was the Managing Director of Takeda UK & Ireland from 2018 – 2022, where he led the integration of Takeda’s significantly expanded presence in the UK & Ireland following the global acquisition of Shire by Takeda in January 2019.  He took over the UKIE Managing Director role after a number of senior positions within the UK business, where he led the Oncology Business Unit, the Gastrointestinal Business Unit and the Marketing Department over the previous 9 years after joining Takeda in 2009.  The performance of Takeda in the UK has been recognised externally by PMEA with Takeda being awarded the ‘UK Company of the Year’ award in 2018, 2019 and 2021.  In his role as Managing Director in UK & Ireland, Jon served for 3 years on the ABPI Board (UK Pharma Trade Association) and he was appointed Co-Chair of the Value and Access workstream and was a member of the Governance Committee within the ABPI.  He also chaired the Japanese Pharma Group (JPG) in the UK, and was Vice-Chair of the Bioindustry Association Rare Disease Industry Group. In his current role, Jon is a member of the PAC (Patient Access Committee) board within EFPIA. Jon previously worked for MSD and Servier and has a strong academic background in pharmacy, gaining his PhD from the University of Nottingham in pharmaceutics & drug delivery and he remains on the UK GPhC Pharmacist register.